Relmada Therapeutics, Inc. (RLMD)

NCM – Real vaqt narxi. Valyuta: USD

6.69

+0.24 (3.72%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

6.69

-0.00 (-0.00%)

Bozordan keyin: Jun 26, 2026, 4:35 PM EDT

11.06.2026

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk's deep expertise in CNS translational science, neuroactive steroid biology, and clinical development will be instrumental in advancing sepranolone, Relmada's GABAA receptor modulator program targeting Prader-Willi Syndrome and other CNS indications.

28.05.2026

Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026.

13.05.2026

Relmada Therapeutics Q1 Earnings Call Highlights

Relmada Therapeutics NASDAQ: RLMD said it remains on track to begin its Phase 3 RESCUE registrational program for NDV-01 in mid-2026 after reporting 12-month Phase 2 data in non-muscle invasive bladder cancer and strengthening its balance sheet through a private financing.

13.05.2026

Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript

12.05.2026

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a durable 80% CR rate at 12 months in the BCG-unresponsive subpopulation, reinforcing best-in-class potential in NMIBC On track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026 Filed provisional patent application with the USPTO in April 2026 covering NDV-01 pharmaceutical formulations and methods of treatment; if issued, patents claiming priority to the provisional filing would have a term until April 2047 Relmada will feature two NDV-01 presentations at the American Urological Association Annual Meeting (AUA2026), highlighting the 12-month Phase 2 data and the Phase 3 RESCUE program design and rationale Cash balance of $234.0 million as of March 31, 2026 expected to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program Management to host a conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., May 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update.

06.05.2026

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2026, and recent business progress.

05.05.2026

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

CORAL GABLES, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the presentation of two abstracts related to NDV-01 at the American Urology Association (AUA2026), taking place from May 15-18 th in Washington D.C.

Videolar

No Data

There is no data to display

Press-relizlar

11.06.2026

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

12.05.2026

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

19.03.2026

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

CORAL GABLES, Fla., March 19, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported audited financial results for the fourth quarter and full year ended December 31, 2025 and provided a corporate update highlighting significant progress across its pipeline.

09.03.2026

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $160.0 million to the Company, before placement agent fees and offering expenses. The PIPE financing included participation from Venrock Healthcare Capital Partners, Commodore Capital, Janus Henderson Investors, RA Capital Management, Balyasny Asset Management, OrbiMed, Spruce Street Capital, Squadron Capital Management, Columbia Threadneedle Investments, Adage Capital Management, Marshall Wace, Braidwell LP, Great Point Partners, LLC and Eventide Asset Management.

Relmada Therapeutics, Inc. (RLMD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Relmada Therapeutics, Inc. (RLMD)

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

Relmada Therapeutics Q1 Earnings Call Highlights

Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

Videolar

No Data

Press-relizlar

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

Relmada Therapeutics Q1 Earnings Call Highlights

Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

Videolar

No Data

Press-relizlar

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Search stocks

Relmada Therapeutics, Inc. (RLMD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Relmada Therapeutics, Inc. (RLMD)

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

Relmada Therapeutics Q1 Earnings Call Highlights

Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

Videolar

No Data

Press-relizlar

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

Relmada Therapeutics Q1 Earnings Call Highlights

Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

Videolar

No Data

Press-relizlar

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing